CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.47 USD
+0.09 (3.57%)
Updated May 20, 2024 03:58 PM ET
After-Market: $2.41 -0.06 (-2.23%) 6:26 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 121 - 140 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
First Patient Enrolled in Piclidenoson Rheumatoid Arthritis Phase 3 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Healthcare - WEEKLY NASH NEWSLETTER: KICK OFF AASLD WITH OUR CALENDAR
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Multiple Clinical Milestones Achieved; Phase 3 Initiation Next; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Multiple Clinical Milestones Achieved; Phase 3 Initiation Next; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Pipeline Progress on Multiple Fronts; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Pipeline Progress on Multiple Fronts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
We are transferring coverage due to the departure of the covering analyst
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
South Korea Distribution Deal Inked; NASH Protocol Submitted; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
South Korea Distribution Deal Inked; NASH Protocol Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
We are re-initiating coverage with a Buy rating and $4 PT.
Provider: Roth Capital Partners, Inc.
Analyst: YANIV S
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G